Should Diagnostic Chemicals Proceed with the Development of the DNA-Based Genetic Testing Instrument?
Francis Erkhart, a local scientist, has recently invented a very promising and relatively simple DNA-based genetic testing instrument that allows doctors to
-threatening diseases. He has approached Diagnostic Chemicals (DC) with his invention in the hope that they wi ll further develop, test, and then commercialize the genetic-testing instrument. Erkha rt wishes to negotiate a contract with DC so his invention can be brought to market as quickly as possible.
The Director of Finance at DC, Janet Morrison, is concerned a bout the risk of the project for the com pa n y. She, together with the R&D Director, estimate that it will take fi ve years to develop and test the instr ument before it is ready for commercialization. Significa n t expenditures will be required during these f ive years; some will be capitalized, some expensed.
To begin with, the company will immediately have to invest $4,000,000 in
new development and testing equipment that has a CCA rate of 40 percent and qualifies for a 10 percent lTC.
Second, the company will have to develop and test the instrument over the next 5 years. These expenditures, provided below, qualify for a 15 percent research a nd development investment tax credit, while the remaining 85 percent is a tax-deductible expense.
Third, for the right to devel op and test the genetic testing instr ument, DC must pay Francis Erkhart $250,000 when the contract is signed. Erk hart will a lso receive a yea rly royalty of 12 percent of a ll sa les associated with the instru ment if it is commercialized.
The risk associated with the project concerns the possibility of commercial
ization and sales if commercialized. Based on various scenarios regarding com mercialization, the possible yearly sales for these scenarios, and the probabilities of the scenarios occurring, Ja net Morrison and the R&D Director have estimated that sal es will average $5.6 million per year, once the testing instrument is com mercialized. If commercialized, the instrument is expected to have a sales life of
While the risks associated with the project are great, so too are the rewards. The d irect costs of producing the genetic testing instrument, if commercialized, are forecast to be only 18 percent of sales. (This is in addition to the 12% of the sales Erkhart receives.) Factory overhead and marketing costs for the instrument are expected to be $800,000 per year.
Furthermore, the provincial government is very interested in ensuring the project proceeds and is a financial success. The province is willing to provide DC with a non-taxable cash grant of $300,000: $150,000 when the contract with Erkhart is signed and $150,000 in 2 years' time. As well, the province is willing
20 CHAPTER CASES
to provide an interest rate buydown of 6 percent on a loan of up to $500,000 for a term of 15 years. Diagnostic Chemicals could borrow $500,000 for 15 years at a rate of 9 percent.
Diagnostic Chemicals's overall cost of capital i s 14.5 percent, but since this project is in another highly risky line of business Janet Morrison feels the compa ny should use a risk-adjusted discount rate of 18.5 percent to evaluate the possi ble investments. The company's tax rate is 23 percent.
a. Should Diagnostic Chemicals proceed with the development of the DNA
based genetic testing instrument? Explain.
See attached for best presentation of requirements.
The expert examines capital budgeting, NPV and calculating cash flows.